Morbidity and mortality associated with prescription cannabinoid drug use in COPD

Canadian cohort study (n=185,876) found higher rates of all-cause mortality among new cannabinoid users vs controls (HR 1.64; 95% CI 1.14–2.39). Those on higher-dose cannabinoids relative to controls also had increased rates of hospitalisation for COPD and pneumonia.

Source:

Thorax